BioArctic

BioArctic Operating Expenses

The Total Operating Expenses of BioArctic (BIOA B.ST) as of Nov 10, 2026 is 492.58 M SEK. In the previous year, Total Operating Expenses was 404.53 M SEK — a change of 21.77% (higher).

Operating Expenses

492.58 MSEK

YoY

21.77%

Last updated:

Total Operating Expenses of BioArctic is 2025 492.58 M SEK. Total Operating Expenses of BioArctic was 2024 404.53 M SEK. It decreases by 21.77% higher compared to the previous year.

The BioArctic Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2018
177.31 M SEK
Jan 1, 2019
103.59 M SEK
Jan 1, 2020
73.61 M SEK
Jan 1, 2021
79.92 M SEK
Jan 1, 2022
189.98 M SEK
Jan 1, 2023
218.10 M SEK
Jan 1, 2024
404.53 M SEK
Jan 1, 2025
492.58 M SEK
The BioArctic Operating Expenses history
YEAROperating ExpensesYoY
492.58 MSEK+21.77%
404.53 MSEK+85.47%
218.10 MSEK+14.81%
189.98 MSEK+137.71%
79.92 MSEK+8.57%
73.61 MSEK-28.94%
103.59 MSEK-41.58%
177.31 MSEK+33.21%
133.11 MSEK+95.14%
68.21 MSEK+59.38%
42.80 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Total Operating Expenses of BioArctic is 492.58 M SEK in 2025.

Total Operating Expenses of BioArctic changed from 404.53 M SEK to 492.58 M SEK, representing a 21.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses BioArctic since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's BioArctic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — BioArctic

All Key Metrics — BioArctic